Insmed earnings missed by $0.07, revenue topped estimates

Insmed (INSM) reported Q3 EPS of -$0.46, missing estimates by $0.07, but revenue of $524.42M exceeded expectations. The stock is down 1.64% over 3 months and 50.07% over 12 months. Analysts have revised EPS 12 times positively and 2 times negatively in the last 90 days. InvestingPro rates its financial health as 'fair performance'.

Original reporting
Published Oct 29, 2026, 11:21 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 11:45 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$INSM
Bearish
high confidence
Mentioned
$INSM
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$INSMBearishLow
01

Why it matters

The EPS miss may trigger sell pressure, while the revenue beat offers a modest positive note.

02

Market read

First‑time earnings release with a mixed beat/miss, relevant for biotech traders.

03

What to watch

Guidance outlook and pipeline updates were not disclosed, leaving upside potential uncertain.

Relevance 8/10Novelty 7/10Timing: after-hours reaction

Background

Insmed (NASDAQ: INSM) is a biotech firm focused on rare pulmonary diseases. The report covers its third‑quarter financial results.

Company-level read

Ticker impact

$INSMBearishHigh confidence
Context

Insmed reported Q3 EPS of -$0.46, missing estimates by $0.07 and revenue of $524.42M beating the $497.11M consensus.

Expected impact

likely downside as market prices in the EPS miss

Evidence & confidence

The EPS shortfall is a fresh, material data point that can move the share price in the near term.

Market effects

Biotech earnings miss may weigh on peer valuations.

U.S. biotech sector could see modest pullback.

Limited to investors tracking biotech earnings.

Counterpoint

Revenue beat could support a short‑term bounce if investors focus on top‑line growth.

Key entities

  • Insmed

    Biopharmaceutical company reporting Q3 results.

Related articles

$INSMHighAI 8/10

Why Did Insmed Stock Jump?

Insmed (INSM) shares rose 15.1% on October 29, 2026, after reporting Q3 2026 results. Revenue of $524.4M beat estimates, but loss per share was wider. BRINSUPRI revenue grew 29% QoQ, and guidance was raised. R&D and sales costs increased 40% YoY. The stock is down 32.5% over the past year.

$INSMHighAI 9/10

Goldman Sachs reiterates Insmed stock rating on Brinsupri beat

Goldman Sachs maintained a Buy rating and $194 price target for Insmed (INSM) after its quarterly results beat estimates. Brinsupri revenue was $400.1M, exceeding expectations. Insmed raised its 2026 guidance for Brinsupri to $1.35B-$1.40B. The stock rose 19.5% to $111.59. Analysts have revised earnings upwards, with price targets ranging from $165 to $243.

$INSMMed

Insmed Inc (INSM) Q3 2026 Earnings Call Highlights: Brinsupri Hits Blockbuster Status

Insmed Inc (INSM) reported positive Q3 2026 earnings, with Brinsupri showing strong persistency and revenue trends. The company expects cash flow positivity in 2027 and provided updates on TPIP trials and Erakase's label expansion. Dr. Martina Flammer highlighted growth opportunities in comorbid COPD and asthma bronchiectasis, with data expected in mid-2027. Insmed also discussed AI use for patient identification and the potential impact of real-world studies.

$INSMMedAI 8/10

What Insmed (INSM) Said on Its Q3 Earnings Call

Insmed (INSM) reported Q3 earnings, highlighting AI diagnostic tools for bronchiectasis, expected to share findings in 2027. FDA granted priority review for ARIKAYCE's sNDA, with a target action date of Jan. 28, 2027. The company expects cash-flow positivity in 2027. Insmed also provided updates on its pipeline, including TPIP and INS1033 programs. Cost of product revenues was $78.2 million, or 14.9% of revenue, with combined R&D and SG&A expenses up 40% year over year.

$INSMHighAI 8/10

Insmed (INSM) Q3 2026 Earnings Call Transcript

Insmed (INSM) reported Q3 2026 revenue of $400.1M for BRINSUPRI, up 29% sequentially. The company raised its 2026 revenue guidance to $1.35B-$1.4B. Insmed expects its lead respiratory assets to exceed $14B in peak sales, with BRINSUPRI potentially reaching $7B+ and TPIP $6B+.